Identifying the signaling pathways and components regulated by direct hepatic GLP-1R stimulation is clinically significant because it may lead to the discovery of novel drug targets and pave the way for the development of medications that can improve NAFLD without requiring weight loss, which is known to be difficult for the majority of obese NAFLD patients [19,47,48]. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.